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Novelty statement: 100 words describing the novelty of the data presented and impact 11 
on the field 12 
• There have been substantial advances in the management and prevention of 13 
cardiovascular disease in diabetes. To understand where unmet needs lie, it is 14 
important to understand the current burden of CVD and the levels of treated and 15 
untreated risk factors.   16 
• In this paper we show that there continues to be a high prevalence of CVD among 17 
people with Type 2 diabetes and a high level of unmet need for risk factor control. 18 
This implies substantial scope for reducing the excess risk of CVD in diabetes 19 
through improved management of known risk factors.   20 
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Abstract 1 
Aims: To describe the prevalence of major cardiovascular disease (CVD) and risk factor 2 
control in a contemporary population with Type 2 diabetes. 3 
Methods: We used data from the national registry in Scotland, SCI-Diabetes, linked to 4 
hospital admissions. Using descriptive statistics and logistic regression we described 5 
associations of risk factors with CVD. CVD was defined based on diagnostic codes in 6 
primary or secondary care data for ischaemic heart disease, cerebrovascular disease 7 
peripheral arterial disease, heart failure, cardiac arrhythmia, hypertensive heart disease, and 8 
revascularisation procedures. 9 
Results: Among 248400 people with Type 2 diabetes with median age 67.5 years 10 
(interquartile range 58.2, 76.1) and median diabetes duration 7.8 years (3.8,13.0), 32% had 11 
prior CVD (35% of men, 29% of women). Median HbA1c overall was 55 mmol/mol (7.2%), 12 
median systolic BP 132 mmHg, median total cholesterol 4.1 mmol/L and mean BMI 32kg/m2. 13 
Overall two-thirds (65% of men, 68% of women) have ≥2 of the following CVD risk factor 14 
thresholds: HbA1c ≥53 mmol/mol (7%), SBP >130 or DBP >80 mmHg, total cholesterol ≥5 15 
mmol/L or BMI ≥30 kg/m2 or were currently smoking. Overall 84% were receiving anti-16 
hypertensives and 75% a statin. Use of metformin was common at 58% but other diabetes 17 
drugs that reduce CVD were rarely used. 18 
Conclusions: There continues to be a high prevalence of CVD among people with Type 2 19 
diabetes and a high level of unmet need for risk factor control. This implies substantial scope 20 
for reducing the excess risk of CVD in diabetes through improved management of known 21 
risk factors.   22 
 23 
Key words: diabetes, cardiovascular disease, cholesterol, blood pressure, smoking, obesity, 24 
glycaemic control  25 
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Introduction  1 
Total mortality rates are currently 40% higher in men and 50% higher in women with Type 2 2 
diabetes mellitus (T2DM) compared to the background population (1). Cardiovascular 3 
disease (CVD) remains the leading cause of loss of life expectancy in Type 2 diabetes and 4 
rates remain elevated compared to those without diabetes. Ongoing elevations in risk have 5 
been reported in recent data from Scotland (2), Sweden and the US for example (3), (4). 6 
Key aspects of the prevention of primary and secondary CVD in diabetes include smoking 7 
prevention, weight control, blood pressure reduction, cholesterol lowering and glycaemia 8 
control. With regards to glycaemic control, evidence of vascular benefit has been 9 
demonstrated for metformin with respect to myocardial infarction and pioglitazone with 10 
respect to CVD, other than heart failure which is increased (5-7). For newer drugs major 11 
cardiovascular outcome trials (CVOTs) have been conducted in recent years (8). In four 12 
drugs from two anti-diabetes drug classes: sodium glucose co-transporter 2 inhibitors 13 
(SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA), evidence of reduced 14 
risk of major CVD events has been demonstrated. These four drugs are canagliflozin 15 
(SGLT2i), empagliflozin (SGLT2i), liraglutide (GLP-1RA), and semaglutide (GLP-1RA). Drug 16 
labels and clinical guidelines are being updated accordingly (9-16), thus it is hoped that the 17 
target of lowering HbA1c in Type 2 diabetes and the major goal of lowering the cause of 18 
excess death will be increasingly achieved. For medical service planning and to understand 19 
current standards of care, it is important to quantify the unmet treatment needs of people 20 
with T2DM, including the prevalence of established CVD and current drug treatment 21 
regimens in a broad and representative Type 2 population. Accordingly, here we aimed to 22 
establish the current prevalence of established CVD in a typical contemporary population 23 
with T2DM. Further, we wanted to investigate the scope for CVD reduction through known 24 
risk factor control by identifying the proportion of people having 2, 3, 4 or more risk factors 25 
for CVD in the Scottish T2DM population. These data are timely given that the EASD / ADA 26 
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are currently revising their joint recommendations on hyperglycaemia management and 1 
since these guidelines are apparently going to highlight “the need to consider the patient’s 2 
important comorbidities, particularly cardiovascular disease or high cardiovascular risk, in 3 
selecting glucose-lowering therapy (17)". 4 
 5 
Methods  6 
Data sources 7 
The Scottish Care Information-Diabetes (SCI-Diabetes) is a register and database that 8 
covers almost all (>99%) of those in Scotland with a diagnosis of diabetes. It has been 9 
described in detail previously (18). It captures data from clinical episodes and laboratory 10 
data in primary care, National Health Service hospital diabetes clinics, community care, and 11 
the national retinopathy screening programme. Using the unique health service identifier it 12 
has been linked to hospital admissions data (Scottish Morbidity Record 01) and to death 13 
data from the National Records of Scotland. Availability of risk factor data was generally 14 
high- being ≥94% for HbA1c, total cholesterol, eGFR, smoking status, blood pressure and 15 
retinopathy status. Availability was lower for albuminuria (82%), BMI (80%), triglycerides 16 
(79%), weight (72%) and LDL cholesterol (56%). However there was no difference in 17 
missingness for those with and without CVD. 18 
 19 
Participants  20 
We defined the study cohort here as all people who were alive, over 18 years of age and 21 
with a clinical diagnosis of Type 2 diabetes as of January 1st, 2016.  22 
 23 
Outcomes 24 
To obtain information on CVD status we selected the Scottish Morbidity Records in-patient 25 
and day case procedure records (SMR01) which use the World Health Organisation - 26 
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International Classification of Disease version 10 (ICD-10) for diagnosis (in earlier years 1 
version 9), and we use the Classification of Interventions and Procedures (OPCS-4) (19). 2 
Each patient’s records were queried for a look back period of ten years.  3 
CVD history was defined as having codes for main cause of admission for any of chronic 4 
ischaemic heart disease (ICD-10 I20-I25), cerebrovascular disease including transient 5 
ischaemic attack (ICD-10 I60-I69 & G45), peripheral arterial disease (ICD-I70.2 and I73.9), 6 
heart failure (III.0, I13 I50), cardiac arrhythmia (I48, I49), hypertensive heart disease (I13.0), 7 
I15.0) or procedure codes for revascularisation procedures of coronary, carotid or lower limb 8 
arteries. Primary care records were also queried for corresponding Read codes for coronary 9 
heart disease, cerebrovascular disease and revascularisation procedures, peripheral 10 
vascular disease and atrial fibrillation (20). 11 
 12 
Other risk factor and covariate data were obtained from SCI-Diabetes on retinopathy 13 
screening status, HbA1c, body weight, body mass index (BMI), blood pressure, estimated 14 
glomerular filtration rate (eGFR), plasma total cholesterol, triglycerides, and urinary albumin 15 
creatinine ratio. The value for these variables nearest in time to January 1st, 2016 was used, 16 
with a maximum look back period of two years. The most recent of the observational records 17 
in the two-year period was selected for each patient. Patient age was calculated at January 18 
1st, 2016. 19 
 20 
Statistical analysis 21 
Simple summary statistics were used to describe the prevalence and distributions of disease 22 
and risk factors. We counted the number of the following risk factor thresholds each person 23 
had; HbA1c ≥53mmol/mol (7%), SBP >130 or DBP >80 mmHg, total cholesterol ≥5 mmol/L or 24 
BMI ≥30 kg/m2 or current smoking. For HbA1c and blood pressure, these thresholds were 25 
chosen to reflect typical clinical guideline intervention levels (5) (21) and for BMI and total 26 
cholesterol were chosen to reflect more extreme lack of control, since most people with 27 
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T2DM require interventions for BMI and warrant lipid lowering therapy. Since for some 1 
people target BP is <140/80 mmHg, we also report these data using this threshold. Logistic 2 
regression was used to quantify the differences in risk factors in those with and without prior 3 
CVD.  4 
 5 
Results  6 
There were 248,400 people with T2DM included. Almost a third (32%) of those with T2DM 7 
had established CVD, the prevalence being 29% (31635/108259) in women and 35% in men 8 
(48962/140141) (Table 1). The prevalence rose from 15% (11249/72894) in those <60 years 9 
to 53% (19987/38096) in those aged 80 years upwards. In this cross-sectional analysis, 10 
those with established CVD were older and more likely to be male and had longer diabetes 11 
duration (Table 1). Adjusted for age, sex and diabetes duration those with CVD had 12 
significantly (p<0.01) higher BMI, higher HbA1c, were more likely to be albuminuric and 13 
currently smoking, and had lower eGFR. Those with CVD had lower age, diabetes duration 14 
and sex-adjusted achieved systolic blood pressure (p<0.01) and cholesterol levels (p<0.01) 15 
to those without a prior history of CVD, on a background of significantly more 16 
antihypertensive and statin therapy (both p<0.01). Overall 58% had a systolic blood pressure 17 
>130 mmHg or a diastolic blood pressure >80 mmHg, with this prevalence being 54% in 18 
those with CVD and 60% in those without CVD. Overall, almost all (97%) of those with CVD 19 
were on at least one antihypertensive drug compared with 77% of those without CVD (Table 20 
1). Of those with CVD, 2% were hypertensive and not on any blood pressure drug, whereas 21 
among those without CVD 11% were hypertensive and not on any anti-hypertensive drug 22 
(Figure 1). Overall, 75% were currently prescribed a statin. Overall 23% (17% of those with 23 
CVD and 26% of those without CVD) had a total cholesterol of 5 mmol/l or more (Table 1). 24 
Among those with CVD 6% had a total cholesterol ≥5 mmol/L and were not on a statin. 25 
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Among those without CVD, 11% had a total cholesterol ≥5 mmol/L and were not on a statin 1 
(Figure 1).  2 
We counted the number of the following risk factor thresholds exceeded by each person; 3 
HbA1c ≥53mmol/mol, SBP >130 mmHg or DBP >80 mmHg, total cholesterol ≥5 mmol/L or 4 
BMI >30 kg/m2 or current smoking. Overall 65% of men and 68% of women with Type 2 5 
diabetes have two or more of these risk factor thresholds (Table 2, supplementary Table 1). 6 
Among those with CVD, 62% had at least two and in those without CVD 69% had at least 7 
two risk factors. At all ages and in both sexes the proportions exceeding these thresholds 8 
was high (Table 2, supplementary Table 1). In the oldest group, aged 80 years and upwards, 9 
the proportions were lowest at 45% of men and 52% of women exceeding two or more 10 
thresholds. This reflected significantly lower proportions exceeding the HbA1c and BMI 11 
thresholds and less smoking in this age group compared to younger age groups 12 
(supplementary Figure 1: p<0.01 for the comparison with the youngest group  adjusted for 13 
sex and diabetes duration). There was more hypertension and more current anti-14 
hypertensive therapy in the older age group (p<0.01 compared to the youngest age group).  15 
The proportions with total cholesterol ≥5mmol/L fell from 35% in those <50 years to 16% in 16 
those aged 80 years and upwards (p<0.01 compared with those <50 years). Statins were 17 
being prescribed in 55% of those aged under 50 years, 80% in those 50-79 years and 70% 18 
in those aged ≥80 years. As expected, at older ages albuminuria and low eGFR were more 19 
common (data not shown). When a cut-off of 140 rather than 130 mmHg was used for 20 
systolic BP the prevalence of those exceeding 2 or more thresholds was 57% overall.  21 
The number of diabetes drugs used was highest in the 50-70 year age bands, falling off   22 
thereafter (Table 3, supplementary Table 2). The numbers of diabetes drugs being used was 23 
similar in those with and without CVD, but the use of insulin was higher in those with CVD 24 
than without. Metformin and pioglitazone use (99% of the TZD/other category shown in 25 
Table 4 comprised pioglitazone) was slightly lower in those with than without CVD (Table 4). 26 
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Overall just 2.4% of those with CVD and 2.9% of those without were on a GLP-1 agonist and 1 
just 1.4% and 2.2% of those with and without CVD respectively were on an SGLT2 inhibitor.   2 
 3 
Discussion  4 
In this study we find a high prevalence of established cardiovascular disease in people with 5 
Type 2 diabetes, with a third of those with diabetes having had a prior CVD. In both those 6 
with and without a CVD history there remains high levels of unmet need with regard to risk 7 
factor control. Overall 65% of men and 68% of women with Type 2 diabetes have two or 8 
more of these risk factor thresholds. At present, targets of HbA1c <58mmo/L are set for most 9 
people with Type 2 diabetes and targets of below 53mmol/L, where safely achievable, are 10 
set in US and UK guidelines (5). However as shown here, just over half achieve the 58 11 
mmol/L target. About a third of people already receive two or more diabetes drugs but these 12 
HbA1c levels suggest that there is scope, at least in some, for intensification of therapy or 13 
switching to different drug classes where existing therapy is not achieving targets. Metformin 14 
and pioglitazone for which there are data showing CVD reduction were slightly less 15 
commonly used in those with than in those without CVD, and the prevalence of use of 16 
pioglitazone was very low at <5%. Of note, the least utilised anti-diabetes drug classes for 17 
people with T2DM in Scotland at this time (2016) were the SGLT2i and GLP-1 agonists. 18 
Since anti-diabetes drugs in these drug classes have been shown to reduce CVD risk and 19 
CVD mortality and this is now influencing guidelines, the pattern should change in the future.  20 
Blood pressure targets in guidelines are set at 130-140 mmHg for systolic and 80-90mmHg 21 
for diastolic pressure, depending on CVD history. However less than half are achieving the 22 
target of <130/80 mmHg and two-thirds the target of <140/80 mmHg (5-7). This is despite 23 
the vast majority of people with Type 2 diabetes being on antihypertensive therapy. So 24 
recognising the need for treatment is not the challenge but rather there may be scope for 25 
further intensification where this is tolerated. Similarly, most people are receiving statin 26 
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therapy, yet total cholesterol levels are high at a mean of 4.1 mmol/L, with 21% exceeding 5 1 
mmol/L. This also suggests scope for more intensive lipid lowering therapy where this is 2 
tolerated. Guidelines also suggest intervention for obesity but more than half of the people in 3 
this study remain obese. Furthermore, a sizeable proportion are current smokers, suggesting 4 
scope for more intensive support for smoking cessation. The proportions exceeding risk 5 
factor thresholds for HbA1c, BMI, total cholesterol and smoking were lowest in those with an 6 
attained age of 80 years or more. This could reflect a survivor effect, or that some who 7 
develop diabetes in later age have less aggressive diabetes phenotypes, as recently 8 
discussed (22). We cannot discern which of these phenomena may underlie this lower risk 9 
factor prevalence at older ages but we note that in contrast to antihypertensive usage the 10 
intensity of diabetes drug use and statin fell in the older age bands, indicating treatment 11 
rates do not explain the HbA1c and lower cholesterol. We cannot comment with these data 12 
on the appropriateness of these lower treatment rates at older ages but they may reflect the 13 
emphasis in national guidelines that diabetes care be tailored to the person’s individual 14 
needs “taking into account their personal preferences, comorbidities, risks from 15 
polypharmacy, and their ability to benefit from long-term interventions because of reduced 16 
life expectancy (5)." 17 
 18 
That further scope for narrowing the gap in life expectancy associated with T2DM may be 19 
achievable by more intensified clinical management of this disease is emphasised by a 20 
recent analysis from the United States, which found that those with diabetes who met 21 
modest treatment goals for HbA1c, non-HDL cholesterol and blood pressure had a 37% 22 
lower mortality than those who did not (23). In that analysis almost half of those with T2DM 23 
had HbA1c above 53mmol/mol (7%) and 14% had an HbA1c of at least 75mmol/mol (9%). In 24 
a recent survey from Denmark (24) of people with T2DM being cared for in primary care, the 25 
risk factor data are overall very similar to these data from Scotland. Specifically, mean age 26 
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was 4 years higher (72 years), smoking prevalence was similar (17%), mean HbA1c was 1 
slightly (3 mmol/mol) lower, systolic blood pressure 2 mmHg lower, diastolic pressure the 2 
same, and total cholesterol just 0.1 mmol/l lower, while rates of lipid lowering drug and 3 
antihypertensive use were very similar. The main difference in current diabetes drugs use 4 
was that in Denmark fewer people (8% compared to 26%) were using sulphonylureas and 5 
more (19% versus 11%) were on insulin therapy. Compared with a summary from the US 6 
NHANES survey data for 2014 for all types of diabetes combined, the risk factor levels are 7 
broadly similar, with mean BMI being about 3 kg/m2 higher in the US, blood pressure about 9 8 
mmHg lower and total cholesterol about 0.7 mmol/L higher in their 2014 survey compared 9 
with these data from Scotland (25). Surprisingly, reported use of antihypertensive (58%) and 10 
lipid lowering drugs (50%) was much less in that study compared to Scotland. In NHANES, 11 
57% were achieving an HbA1c <53mmol/mol (7%) compared with 43% in Scotland. There 12 
were 15% current smokers compared with 17% in Scotland. (25) 13 
 14 
Our definition of CVD was wide, capturing not just coronary heart disease (CHD) and 15 
cerebrovascular disease but also cardiac arrhythmia, peripheral arterial disease and related 16 
revascularisations. Restricting the definition to prior CHD or cerebrovascular disease or 17 
coronary revascularisation procedures or heart failure would yield a prevalence of 28%. On 18 
the other hand if we define CVD based on the entry criteria in the LEADER trial, then 44% of 19 
our population met this definition (12). Clearly the burden of established CVD is large under 20 
any definition used.  21 
 22 
Our data are of substantial interest in understanding what percentage of people with 23 
diabetes have unmet need for CVD prevention therapies. In particular, whilst new diabetes 24 
drugs are being licensed based on efficacy for HbA1c and lack of harm for CVD, there is now 25 
evidence of cardiovascular benefit for some. New diabetes therapies that have shown 26 
11
 
 
 
benefit with regard to CVD reduction offer scope for simultaneous improvement in HbA1c 1 
whilst lowering CVD risk. For the SGLT2 inhibitor empagliflozin the hazard ratio for CVD was 2 
0.86; (0.74 to 0.99) (9) and for canagliflozin it was 0.86 (0.75 to 0.97) (10). For the GLP-1 3 
agonist semaglutide a hazard ratio versus placebo of 0.74 (0.58 to 0.95) for CVD was 4 
observed (11) and for liraglutide 0.87 (0.78 to 0.97) versus placebo (12) but for lixisenatide 5 
the hazard ratio versus placebo was 1.02 (0.89 to 1.17) (13). Trials of the the DPP-4 inhibitor 6 
sitagliptin (14) alogliptin (15) and saxagliptin (16) have not shown these reductions. Several 7 
more large CVOTs will be reporting in the next 2 years (8,26). These data from 2016 predate 8 
changes in guidelines and licencing for many of the new diabetes drugs and show very low 9 
rates of use of diabetes drugs with evidence of CVD prevention other than metformin. 10 
This study aimed to give a brief contemporary snapshot of Type 2 diabetes and its 11 
management. Limitations are that for some risk factors data were incomplete. However the 12 
similarity in missingness between CVD status groups and the fact that the sample size with 13 
available data is large in all strata, means that imputation is not needed and our estimates 14 
have precision and are free of missing data bias or confounding. Another limitation is that we 15 
do not have data on why those with elevated risk factors seem to be insufficiently treated 16 
based on their risk factors – i.e. whether this is under-prescribing, non-adherence or side 17 
effect issues.  A key aspect of our paper is that the sample is large and representative of the 18 
Scottish population. 19 
 20 
 21 
In conclusion 22 
We found that there continues to be a high prevalence (32%) of CVD among people with 23 
diabetes and a high level of unmet need with regard to risk factor control. This implies 24 
substantial scope for further reduction in the relative risk of CVD associated with diabetes 25 
12
 
 
 
through adherence to healthy lifestyles and use of drugs that reduce CVD and control of 1 
known risk factors, including but not restricted to HbA1c.  2 
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Figure 1: Statin & anti-hypertensive use by risk factor threshold and CVD status 1 
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